Healthcare information exchange is an important research topic, which can benefit both healthcare providers and patients. In healthcare data sharing, many cloud-based solutions have been proposed, but the trustworthiness of a third-party cloud service is questionable. Recently, blockchain has been introduced in healthcare record sharing, which does not rely on trusting a third party. However, existing approaches only focus on the records collected from medical examination. They are not efficient in sharing data streams continuously generated from sensors and other monitoring devices. Today, IoT devices have been widely deployed and sensors and mobile applications can monitor patients’ body conditions. The collected data are shared to laboratories and institutions for diagnosis and further study. Moreover, existing approaches are too rigid to efficiently support metadata change. In this paper, an efficient data-sharing scheme is proposed, called MedChain, which combines blockchain, digest chain, and structured P2P network techniques to overcome the above efficiency issues in the existing approaches for sharing both types of healthcare data. Based on MedChain, a session-based healthcare data-sharing scheme is devised, which brings flexibility in data sharing. The evaluation results show that MedChain can achieve higher efficiency and satisfy the security requirements in data sharing.

Current pharmaceutical formulation development still strongly relies on the traditional trial-and-error methods of pharmaceutical scientists. This approach is laborious, time-consuming and costly. Recently, deep learning has been widely applied in many challenging domains because of its important capability of automatic feature extraction. The aim of the present research is to apply deep learning methods to predict pharmaceutical formulations. In this paper, two types of dosage forms were chosen as model systems. Evaluation criteria suitable for pharmaceutics were applied to assess the performance of the models. Moreover, an automatic dataset selection algorithm was developed for selecting the representative data as validation and test datasets. Six machine learning methods were compared with deep learning. Results showed that the accuracies of both two deep neural networks were above 80% and higher than other machine learning models; the latter showed good prediction of pharmaceutical formulations. In summary, deep learning employing an automatic data splitting algorithm and the evaluation criteria suitable for pharmaceutical formulation data was developed for the prediction of pharmaceutical formulations for the first time. The cross-disciplinary integration of pharmaceutics and artificial intelligence may shift the paradigm of pharmaceutical research from experience-dependent studies to data-driven methodologies.

Oral disintegrating tablets (ODTs) are a novel dosage form that can be dissolved on the tongue within 3 min or less especially for geriatric and pediatric patients. Current ODT formulation studies usually rely on the personal experience of pharmaceutical experts and trial-and-error in the laboratory, which is inefficient and time-consuming. The aim of current research was to establish the prediction model of ODT formulations with direct compression process by artificial neural network (ANN) and deep neural network (DNN) techniques. 145 formulation data were extracted from Web of Science. All datasets were divided into three parts: training set (105 data), validation set (20) and testing set (20). ANN and DNN were compared for the prediction of the disintegrating time. The accuracy of the ANN model have reached 85.60%, 80.00% and 75.00% on the training set, validation set and testing set respectively, whereas that of the DNN model were 85.60%, 85.00% and 80.00%, respectively. Compared with the ANN, DNN showed the better prediction for ODT formulations. It is the first time that deep neural network with the improved dataset selection algorithm is applied to formulation prediction on small data. The proposed predictive approach could evaluate the critical parameters about quality control of formulation, and guide research and process development. The implementation of this prediction model could effectively reduce drug product development timeline and material usage, and proactively facilitate the development of a robust drug product.

Legacy electronic health record systems were not developed with the level of connectivity expected from them nowadays. Therefore, interoperability weakness inherent in the legacy systems can result in poor patient care and waste of financial resources. Simultaneously, healthcare providers are not yet ready to dispose of them. Large hospitals are also less likely to share their data with external care providers due to economic and political reasons. To overcome the barriers in the effective medical data exchange process, we present a novel hybrid cloud called MedShare, dealing with interoperability issues among disconnected but autonomously functioning healthcare providers. The proposed system architecture and its implementation is based upon: 1) custom data extractors to extract legacy medical data from the three hemodialysis centers under consideration; 2) negotiated and converted to a common data model in each of the private cloud of a provider; 3) indexed patient information using the HashMap technique into the public cloud that operates on private clouds, called a hybrid cloud; and 4) a set of services and tools installed as a coherent environment to exchange information smoothly. This paper enables healthcare professionals to appropriately access and securely share a patient's medical information. MedShare allows the healthcare providers and administrators to maintain the control of their patient data, which is always the primary concern in building a trustworthy environment for exchanging patient information. Medshare effectively addresses primary security and privacy concerns surrounding the deployment of data exchange process by including patient consent and a two-way authorization process.